Core Insights - UBS identifies five long-term investment themes that currently present the most attractive opportunities: Digital Consumers, Empowering Technologies, Diversity and Equality, Family Businesses, and Exploring New Frontiers [1] Group 1: Digital Consumers - The younger generation, as digital natives, has different consumption patterns compared to their parents, influencing their behaviors [2] - The theme ranks first among UBS's long-term investment themes due to high quality metrics, involving companies with strong balance sheets and high returns on invested capital [2] - The theme benefits from the robust performance of the technology sector driven by AI trends, although it is noted that valuations are relatively high [2] Group 2: Empowering Technologies - UBS identifies five key empowering technologies: AI, AR/VR, Big Data, Blockchain, and other disruptive technologies, which are expected to transform various industries [3] - The market size for these technologies is projected to grow from $287 billion in 2022 to $3.2 trillion by 2030, with AI expected to account for 90% of this growth [3] - The theme maintains a strong position in UBS's long-term investment themes due to its high momentum score, particularly favoring the information technology sector [3] Group 3: Diversity and Equality - UBS anticipates improvements in global regulatory frameworks for information disclosure and fairness, which could enhance GDP over the next decade [4] - Companies that promote diversity and equality throughout their value chains are expected to perform well in the long term [4] - The theme remains a top investment choice due to favorable valuations and quality scores, with a balanced distribution across various industries [5] Group 4: Family Businesses - Family businesses account for two-thirds of global enterprises and contribute over 70% of global GDP, providing significant employment [6] - UBS estimates that family businesses represent 20-30% of global stock market value, benefiting from conservative financial management and capital discipline [6] - The theme is expected to leverage economic recovery, particularly in Europe, where industrial activity is projected to improve by 2026 [7] Group 5: Exploring New Frontiers - Emerging and frontier economies are seen as key drivers of global GDP growth over the next decade, with demographic factors playing a crucial role [8] - UBS believes that these markets offer attractive returns and diversification opportunities, despite being inherently riskier [8] - The increasing U.S. fiscal deficit and a weakening dollar are making emerging markets more appealing for investors seeking to diversify away from U.S. assets [8] Group 6: Short-term Headwinds for Gene Therapy and Digital Health - Gene therapy and digital health themes currently rank low in UBS's quantitative model, facing short-term headwinds and lower valuation attractiveness [9] - The biotechnology sector, particularly small-cap firms, is experiencing significant capital acquisition challenges, impacting their operational environment [10] - Despite the potential of AI applications in healthcare, the current landscape lacks scalable, data-driven growth drivers, leading to a cautious outlook for these themes [11]

Summary of Solid Biosciences FY Conference Call Company Overview - **Company**: Solid Biosciences (NasdaqGS:SLDB) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 13, 2026 - **CEO**: Bo Cumbo Key Points Industry and Company Developments - Solid Biosciences has dosed 33 patients in its phase 1/2 Duchenne muscular dystrophy (DMD) trial called Inspire, reporting no drug-induced liver injury, myocarditis, or AHUS [2][30] - The company has successfully enrolled its first patient in a double-blind placebo-controlled trial and dosed its first patient in Friedreich's ataxia (FA) [2][5] - Solid has established over 50 partnerships for its capsid technology, indicating a growing interest in its platform for next-generation therapies [3][6] Clinical Trials and Pipeline - The Inspire trial aims to enroll 50 to 60 patients, with 33 already dosed and full enrollment expected soon [8][31] - The company is prioritizing FA over CPVT (catecholaminergic polymorphic ventricular tachycardia) due to resource constraints, with plans to dose patients in CPVT this quarter [5][6] - The first patient in the double-blind placebo-controlled trial will be dosed in either Australia or Canada, with European sites also opening [9][32] Safety and Efficacy Data - The safety profile of the therapy appears robust, with 0% drug-induced liver injury and other serious adverse events reported [11][30] - The mean expression of microdystrophin in treated patients is reported at 58%, the highest among current therapies [10][23] - Early cardiac data shows declines in troponin levels and increases in ejection fraction, suggesting potential cardiac benefits [11][28] Capsid Technology - The capsid SLB101 is designed for enhanced binding to muscle tissue, leading to improved distribution and reduced liver targeting [12][19] - The capsid technology is noted for its low viral load (1E14), which is lower than other therapies, potentially leading to fewer side effects [14][40] - The capsid's unique design allows for better muscle perfusion and reduced fibrosis, contributing to the observed clinical benefits [13][19] Market Opportunity - The DMD market is expanding, with approximately 100 boys born with the disease each quarter, indicating a high demand for new therapies [36] - Solid aims to be a leader in the DMD space, with plans for accelerated approval pathways and potential first gene therapy to market in the UK [36][44] Regulatory Strategy - The company is preparing for multiple meetings with the FDA to discuss the phase 3 placebo-controlled trial and the potential for accelerated approval [33][44] - Solid has not reviewed any functional data to maintain the integrity of its discussions with the FDA, ensuring confidence in its regulatory submissions [34][45] Future Milestones - Solid plans to continue dosing patients and gathering data throughout the year, with significant milestones expected that could transform the company [38][39] - The company is focused on ensuring that its therapies are well-positioned for market entry and regulatory approval, with ongoing studies to track long-term outcomes [29][44] Additional Insights - The dual-route administration in FA is a significant milestone, showcasing the company's innovative approach to treatment delivery [37] - The emphasis on safety and efficacy data, along with a strong pipeline, positions Solid Biosciences as a key player in the gene therapy landscape for muscular dystrophies [12][30]

Company Performance & Financials - BeOne Medicines delivered significant product revenue growth, with a 43% increase in the first three quarters of 2025 [17] - BRUKINSA rapidly became the global BTKi leader, showing a 51% increase in approved indications [20] - The company's pipeline achieved proof of concept for 6 assets across 4 modalities and brought 5 new molecular entities (NMEs) to the clinic in 2025 [22] CLL Treatment Landscape & BRUKINSA - BRUKINSA demonstrates progression-free survival (PFS) superiority to ibrutinib, with a hazard ratio (HR) of 069 (95% CI: 055, 087), p-value: 00014 [53] - Recent competitor efficacy data does not indicate a change to the CLL treatment landscape, with Pirtobrutinib showing a HR of 0845 (95% CI: 0566-1262), p-value: 04102 [60] - In the ALPINE trial, Zanubrutinib had a lower rate of adverse events (AEs) leading to treatment discontinuation at 77% compared to ibrutinib at 130% [65] ZS (Zanubrutinib + Sonrotoclax) Regimen - ZS (Zanubrutinib + sonrotoclax) is poised to be a fixed duration regimen with a 91% undetectable minimal residual disease (uMRD) rate [74] - ZS showed a 100% 36-month PFS rate (at 30 months) [74] - The company is initiating a Phase 3 trial of ZS vs AV in 1L CLL in H1 2026 [101] Pipeline & Future Milestones - The company has approximately 8-10 new molecular entities (NMEs) per year in its pipeline [105] - BeOne is the only company with best-in-class foundational medicines across the three key mechanisms of action (MOAs) in CLL [99] - The company anticipates several milestones in H1 and H2 2026, including Phase 3 data for BRUKINSA+R vs BR in 1L MCL and a potential R/R MCL U S approval for Sonro [101]

Lexeo Therapeutics Conference Call Summary Company Overview - **Company**: Lexeo Therapeutics (NasdaqGM:LXEO) - **Product**: LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (ACM) Key Industry Insights - **Disease Context**: PKP2-associated ACM affects approximately 60,000 people in the U.S. and is characterized by high risks of cardiac rhythm abnormalities, heart failure, and sudden cardiac death. Over 20% of patients experience sudden cardiac death as their first symptom [doc id='6'][doc id='14']. - **Current Treatment Limitations**: Existing treatments, including ICDs and medications like beta-blockers, do not address the underlying genetic cause of the disease [doc id='7'][doc id='14']. Core Findings from Clinical Trial - **Trial Design**: The Heroic PKP2 phase 1-2 clinical trial is an open-label, single-arm, multicenter trial assessing the safety and efficacy of LX2020 [doc id='15']. - **Participants**: 10 participants have been dosed, with 8 having at least six months of follow-up. The cohort includes patients with advanced disease progression, averaging nine years since diagnosis [doc id='16'][doc id='17']. - **Safety Profile**: LX2020 has been well tolerated with no serious adverse events reported. Some participants experienced elevated liver function tests, which were managed successfully [doc id='18'][doc id='19']. Efficacy Data - **PKP2 Protein Expression**: Significant increases in PKP2 protein expression were observed, with robust vector copy number and mRNA levels indicating effective transduction [doc id='20'][doc id='21']. - **Arrhythmia Burden Reduction**: - **Premature Ventricular Contractions (PVCs)**: A mean improvement of 14% was noted in the high-dose cohort, with stabilization or reduction in PVCs for the majority of participants [doc id='5'][doc id='23']. - **Non-Sustained Ventricular Tachycardia (NSVT)**: A mean improvement of 22% was observed in the high-dose cohort, with reductions in NSVT events indicating a potential decrease in the risk of sustained VT and ICD shocks [doc id='5'][doc id='23']. - **Clinical Measures**: Participants showed stabilization in cardiac function, with no changes in New York Heart Association Class reported [doc id='26']. Future Outlook - **Next Steps**: Enrollment for the Heroic study was completed in Q4 2025, with plans to provide twelve-month follow-up data for all high-dose participants by Q4 2026 [doc id='27']. - **Regulatory Engagement**: Discussions with the FDA regarding future trials and endpoints, particularly focusing on NSVT as a key measure, are anticipated [doc id='37']. Additional Considerations - **Patient Variability**: The trial includes patients with varying disease severity, which may influence the observed efficacy and safety outcomes [doc id='36']. - **Long-term Expectations**: There is optimism regarding the potential for further improvements in arrhythmia burden and cardiac function as data matures [doc id='47']. This summary encapsulates the key points from the Lexeo Therapeutics conference call, highlighting the company's focus on addressing a significant unmet medical need in the treatment of PKP2-associated arrhythmogenic cardiomyopathy through innovative gene therapy.

Core Insights - The French pharmaceutical industry is recognized for its strong innovation capabilities and quality reputation on the international stage, with over 260 pharmaceutical companies and more than 400 production bases as of September 2024 [1][2] - France's pharmaceutical exports reached €33.4 billion in 2023, contributing to a trade surplus of €2 billion, making it the fourth largest surplus industry in the country [1] - France ranks as the fifth largest pharmaceutical market globally, holding a 2.9% share of the global market, second only to Germany in Europe [2] Factors Contributing to Prosperity - High levels of R&D investment, vibrant industrial clusters, and talent cultivation are key drivers of the French pharmaceutical industry's success, with over 12% of industry revenue allocated to R&D in recent years [3] - Sanofi's R&D spending has increased to 18% of its revenue for 2024, while Ipsen plans to allocate around 20% of its revenue to R&D [3] - The Paris-Saclay cancer cluster exemplifies an innovative ecosystem, fostering collaboration among academia and industry in cancer research [3][4] Talent Development - French pharmaceutical companies prioritize talent development, with firms like Servier actively engaging in local educational networks and offering training programs [4] Challenges Faced - Despite its strengths, the French pharmaceutical industry faces significant challenges, including a declining market share over the past 20 years, particularly in the vaccine sector, where France's global export share dropped from 23% in 2000 to 14% in 2020 [5] - The market has experienced sluggish growth, with the net sales of pharmaceuticals reaching €26.1 billion in 2023, but failing to alleviate the growing deficit in public healthcare [6] - Talent retention is a critical issue, with average monthly salaries for researchers around €3,600 lacking competitiveness in Europe, and a high instability rate of 33% in employment within higher education and public research [6]

Core Insights - Jefferies has released a report on the outlook for the U.S. biotech industry in 2026, highlighting key clinical trial data disclosures, new drug approvals, and policy dynamics that could lead to value re-evaluation for companies in the sector [1] Six Preferred Stocks - Jefferies identified six companies as core recommendations for 2026 based on market catalysts and valuation potential: - Dianthus Therapeutics (DNTH.US), target price $66: Focused on claseprubart for various neuromuscular diseases, with peak revenue estimated at $2 billion [2] - Taysha Gene Therapies (TSHA.US), target price $11: TSHA-102 for Rett syndrome, with peak revenue potential of $2 billion and a key trial data disclosure expected by the end of 2026 [2] - Tyra Biosciences (TYRA.US), target price $32: Dabogratinib for bladder cancer and achondroplasia, with critical data expected next year [3] - Tango Therapeutics (TNGX.US), target price $14: Collaboration with Revolution Medicines for a pancreatic cancer treatment, with data expected in mid-2026 [3] - ORIC Pharmaceuticals (ORIC.US), target price $23: Two potential assets targeting prostate cancer and lung cancer, with key data expected next year [4] - Solid Biosciences (SLDB.US), target price $15: Focused on gene therapy for Duchenne muscular dystrophy, with critical meetings with the FDA planned for 2026 [4] Seven Undervalued Companies - The report also highlighted seven undervalued companies with significant catalysts: - Ultragenyx Pharmaceutical (RARE.US), target price $114: Expected key catalysts in 2026, including data for treatments for osteogenesis imperfecta and Angelman syndrome [5] - Beam Therapeutics (BEAM.US), target price $41: Updates on AATD therapy and SCD therapy expected in 2026, showcasing strong potential [5] - Aurinia Pharmaceuticals (AUPH.US), target price $21: Steady growth in lupus nephritis treatment, with new drug development paths expected to expand growth [6] - Kodiak Sciences (KOD.US), target price $39: Anticipated data from three pivotal trials in 2026, with significant potential for stock volatility [7] - Intellia Therapeutics (NTLA.US), target price $45: Key data for hereditary angioedema therapy expected in mid-2026, with sufficient cash reserves to support operations [7] - Compass Therapeutics (CMPX.US), target price $8: Data for cholangiocarcinoma therapy expected in early 2026, with a significant market opportunity [8] - KalVista Pharmaceuticals (KALV.US), target price $38: First oral treatment for hereditary angioedema expected to see rapid growth in 2026 [8] Five Potential Acquisition Targets - Jefferies identified five companies that may become acquisition targets in 2026 due to their unique assets or market positions: - Arrowhead Pharmaceuticals (ARWR.US): Strong RNAi product line for cardiovascular and metabolic diseases [9] - Celcuity (CELC.US): Unique efficacy of gedatolisib in breast cancer [9] - ORIC Pharmaceuticals: High-value prostate and lung cancer projects [9] - Travere Therapeutics (TVTX.US): Potential for significant market expansion in rare kidney diseases [9] - KalVista Pharmaceuticals: First-mover advantage in oral HAE treatment [9]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Frontera Therapeutics （於開曼群島註冊成立的有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資訊予香港公眾人士。 本 申 請 版 本 為 草 擬 本，其 內 所 載 資 料 並 不 完 整，亦 可 能 會 作 出 重 大 變 動。 閣 下 閱 覽 本 文 件，即 代 表 閣下知悉、接納並向本公司、其保薦人、整體協調人、顧問或承銷團成員表示同意： 本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》呈交香港公司註冊處處長登記前， 本 公 司 不 會 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請。倘 於 適 當 時 候 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請，準 投 資 者 務 請 僅 依 據 呈 交 香 港 公 司 註 冊 處 註 冊 的 ...

Investment Rating - The report does not explicitly provide an investment rating for the biopharmaceutical sector [5]. Core Insights - The biopharmaceutical sector is experiencing significant activity with multiple companies focusing on innovative drug development, particularly in the area of siRNA targeting INHBE, which shows promise for fat reduction without muscle loss [3][24]. - The report highlights the recent performance of new drug stocks, with notable gains from companies such as Saint Nor Pharmaceutical (+30.88%) and Dongyao Pharmaceutical (+16.37%), while companies like Kexin Pharmaceutical (-14.19%) and Rongchang Biotechnology (-10.09%) faced declines [1][15]. - There is an expectation of multiple catalysts in the sector, including academic conferences and data releases, which could drive further interest and investment [2]. Weekly New Drug Market Review - From December 8 to December 14, 2025, the new drug sector saw significant stock movements, with the top five gainers and losers listed [1][15]. - The report notes that there were no new drug approvals during this week, but 11 new drug applications were accepted [4][31]. Weekly New Drug Industry Analysis - Wave Life Sciences has reported promising initial data for its siRNA drug WVE-007, which targets INHBE and demonstrates potential for reducing visceral fat while preserving muscle mass [3][24]. - The report indicates that several companies, both globally and domestically, are actively developing siRNA drugs targeting INHBE, with five drugs already in clinical development [27][28]. Weekly New Drug Approval & Acceptance Status - No new drug or new indication approvals were reported this week, but 11 new drug applications were accepted [4][31]. - A total of 55 new drug clinical applications were approved, and 47 new drug clinical applications were accepted during the week [9][34]. Key Events in Domestic Market - Significant events include the approval of new drugs by companies such as Zhengda Tianqing and Nuo Cheng Jian Hua, which received approval for their respective new drugs [10][11]. Key Events in Overseas Market - Noteworthy overseas events include Eli Lilly's announcement of positive results from its TRIUMPH-4 Phase 3 trial and the FDA's approval of a gene therapy by Fondazione Telethon [11].

Core Points - Tenaya is presenting initial data from Cohort 1 of the RIDGE-1 Phase Ib/II clinical trial for TN-401 gene therapy aimed at treating PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) [1][2] Group 1 - The presentation is led by Michelle Corral, Vice President of Corporate Communications and Investor Relations at Tenaya [1] - Key executives participating in the call include Faraz Ali (CEO), Dr. Kathy Ivey (SVP of Research), and Dr. Whit Tingley (Chief Medical Officer) [2] - A PDF of the presentation slides is available on Tenaya's website in the Investor Relations section [2] Group 2 - The information shared during the call includes forward-looking statements reflecting the company's perspective as of December 11, 2025 [3] - Investors are cautioned against placing undue reliance on the forward-looking statements due to inherent assumptions [3] - The company will not be taking questions during this call due to the launch [4]

Lexeo Therapeutics Conference Call Summary Company Overview - **Company**: Lexeo Therapeutics (NasdaqGM:LXEO) - **Focus**: Development of gene therapies for genetically mediated cardiovascular diseases, specifically targeting Arrhythmogenic Cardiomyopathy (ACM) Key Points Discussed Industry and Disease Context - **Disease**: Arrhythmogenic Cardiomyopathy (ACM), particularly related to mutations in the PKP2 gene - **Prevalence**: Approximately 125,000 individuals in the U.S. are diagnosed with ACM, with about 20% presenting due to sudden cardiac arrest [9][10] - **Genetic Basis**: Mutations in the PKP2 gene account for over 50% of ARVC ACM cases, leading to significant electrical and structural abnormalities in the heart [10][12] Clinical Insights and Management - **Holistic Approach**: Emphasis on a comprehensive management strategy for ACM, integrating genetic testing and precision medicine [4][8] - **Diagnostic Criteria**: Utilization of Task Force criteria for diagnosing ACM, which includes both structural and electrical evaluations [14][17] - **Management Strategies**: - Initial treatment often involves beta-blockers for arrhythmias [28] - Implantable cardioverter-defibrillators (ICDs) are considered for high-risk patients [29] - Antiarrhythmic medications like flecainide and sotalol may be used as the disease progresses [30] - Ablation procedures are an option if medical management fails, though they do not address the underlying disease progression [32][33] Gene Therapy Potential - **Gene Therapy Candidate**: LX2020, currently in clinical trials for treating PKP2-associated ACM [4][42] - **Patient Selection**: Ideal candidates for gene therapy are those with early signs of disease, particularly those experiencing symptomatic arrhythmias [36][70] - **Expected Outcomes**: Aiming to reduce arrhythmias and prevent progression to heart failure, with a focus on improving electrical stability in the heart [39][40] Future Directions - **Clinical Trials**: Anticipation of data updates on LX2020 in early 2026, with a focus on clinical endpoints and pathological studies [78] - **Adoption of Gene Therapy**: High expected uptake among patients who have experienced severe arrhythmias, with estimates suggesting 70-90% readiness for gene therapy [71][72] Additional Considerations - **Family Screening**: Importance of genetic testing for family members of diagnosed patients to identify at-risk individuals [20][62] - **Disease Progression**: Variability in disease progression rates among patients, with those experiencing sudden cardiac arrest likely to progress more rapidly [86][87] Conclusion - Lexeo Therapeutics is at the forefront of developing innovative gene therapies for ACM, with a strong emphasis on precision medicine and holistic patient care. The upcoming clinical data on LX2020 is highly anticipated and could significantly impact treatment paradigms for ACM patients.